The Pharmaceutical Care Management Association notched another victory in its legal battle against state laws regulating pharmacy benefit managers, when the Eighth Circuit on Friday agreed with the association that North Dakota’s statute can’t exist alongside federal benefits law.

Selecta Biosciences Inc.'s board was hit with a Delaware lawsuit claiming it arranged an underpriced share sale to benefit four of its members the day before news that was “bound to significantly boost” the gene therapy company’s market value.

Federal safety officials aren’t issuing a national coronavirus exposure rule, so state and local governments are taking matters into their own hands by enacting Covid-19 workplace protection mandates.

Negotiations on a new coronavirus relief bill edged toward the brink of collapse after a meeting Thursday between White House officials and top congressional Democrats ended with each side accusing the other of being unwilling to compromise and the biggest issues far from resolved.

Biogen Inc.’s experimental Alzheimer’s disease treatment aducanumab was granted priority review status by U.S. regulators, a move that could hasten the drug’s arrival on the market.

Pfizer said it reached a multi-year agreement with Gilead Sciences to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for Covid-19.